ClinicalTrials.gg
Not yet recruitingNCT06710431Updated Nov 29, 2024

A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

A Phase 2 interventional study of AFA-281 in Alcohol Abuse, Alcohol Abuse/addiction and Anxiety, sponsored by Afasci Inc. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Afasci Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,073 studies in Alcoholism with a site in United States — 187 open to participants now, 227 under way, 15 of them phase 3. Alcoholism · United States.

Planned enrollment
713th of 989
36 · median 80
Started
2025
with 55 others
Phase 2
247 of 1,073
38 open now
Primary completion
2027-06
later than 106 of 226 live
Registered
984th of 1,073
by date

Among the 1,073 studies in Alcoholism with a site in United States, this one is the 713th largest by planned enrollment of the 989 interventional ones that give a count, is one of 56 that started in 2025, is one of 247 in phase 2, reaches primary completion later than 106 of the 226 other live ones, and was the 984th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

187 of the 1,073 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:

182 more — sign in →

All 187 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,073 studies in Alcoholism with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and exploratory efficacy of AFA-281 in patients with Alcohol use disorder on cravings, subjective response to alcohol, pain thresholds, anxiety, depression, and sleep.

Read the detailed description

This study will determine the safety, tolerability, and exploratory efficacy of AFA-281. This study is a randomized, double-blind, placebo-controlled, human laboratory study of 36 community-based, non-treatment-seeking male and female individuals with current (i.e., past month) moderate-to-severe AUD (DSM-5). This study will be conducted by Dr. Lara Ray at UCLA. The total study duration is approximately 42 days including a 2-week screening period. Eligible participants will be randomized into one of three cohorts: 60 mg AFA-281, 120 mg AFA-281, or Placebo. Participants will start at a lower dose and increase the dose over 2 weeks then continue to maintain the dose for an additional 2 weeks. In week 4, participants will complete 7 daily visits to complete assessments and questionnaires.

03

Conditions studied

  • Alcohol Abuse
  • Alcohol Abuse/addiction
  • Anxiety
  • Pain Threshold
  • Depression Disorders
  • Sleep Disorder

Keywords

  • AFA-281
  • alcohol abuse
  • alcohol
  • depression
  • pain threshold
  • sleep disorder
  • anxiety
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 21 and 65
  2. Must voluntarily sign and date each , approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.
  3. Meet current (i.e., past 12 months) diagnostic criteria for moderate or severe AUD
  4. Report drinking at least 28 drinks per week if male, 21 drinks per week if female, in the 28 days prior to consent.
  5. Must be surgically sterile (vasectomy, tubal ligation, or hysterectomy) or agree to be sexually inactive or agree to use a barrier method of (i.e., condom) from the start of screening until study completion, and agree to refrain from donating sperm for 90 days after study drug administration.

Exclusion criteria

Exclusion Criteria:

  1. Current treatment for alcohol use or a history of treatment in the 30 days before enrollment or treatment seeking
  2. Current (last 12 months) diagnosis of dependence on any psychoactive substances other than nicotine
  3. Current DSM-5 diagnosis of substance use disorder for any substance other than alcohol and nicotine
  4. Lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder
  5. Current DSM-5 major depressive disorder with suicidal ideation
  6. Positive urine screen for narcotics, amphetamines, or sedative hypnotics
  7. alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised
  8. Pregnancy, nursing, or refusal to use reliable method of if female
  9. History of significant sensitivity to any drug.
  10. Has a clinically significant abnormal or an ECG with a corrected for heart rate using the Fridericia formula (QTcF) > 430 ms.
  11. History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma), renal, hepatic, gastrointestinal, hematologic, endocrine, dermatological, metabolic or psychiatric disease or disorder, or any uncontrolled medical illness.
  12. Has an estimated (CrCl) outside of normal range.
  13. History of head trauma with loss of consciousness, seizures or convulsions, including febrile, alcohol or drug withdrawal seizures.
  14. History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH, or absorption.
  15. Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), surface antigen (HBsAg), virus antibody (HCV Ab), or antibodies (HIV Ab). Negative HIV status will be confirmed at Screening and the results will be maintained confidentially by the study site.
  16. Liver enzymes , ALT, or GGT ≥ 3 times upper normal limit.
  17. Positive urine drug screen for drugs of abuse at Screening or Day -1.
  18. Receipt of any drug by injection within 30 days prior to study drug administration.
  19. A clinically notable vital sign abnormality including a history of syncopal or near syncopal events following abrupt change in posture.
  20. Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration.
  21. Pregnant or nursing women.
  22. Receipt of any products within 6 weeks prior to study drug administration.
  23. Current enrollment in another clinical study.
  24. Previous enrollment in this study.
  25. Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to participate in the AFA-281 Phase I1a Study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
36 participants (estimated)

Study arms

  • Placebo comparator
    AFA-281 placebo control

    AFA-281 placebo control group

    Drug: AFA-281

  • Active comparator
    Low dose of AFA-281

    AFA-281 at 60 mg per day

    Drug: AFA-281

  • Active comparator
    High dose AFA-281

    AFA-281 at 120 mg per day

    Drug: AFA-281

Interventions

06

What researchers measure

Primary outcomes

  1. Cue-induced alcohol craving

    Questionnaire measures the level of alcohol craving

    Time frame: predose and weekly through Week 4

  2. Stress-induced alcohol craving

    Alcohol urge questionnaire after stressful stimuli

    Time frame: predose and weekly through Week 4

  3. Subjective response to alcohol

    Biphasic alcohol effects scale and profile of negative mood states

    Time frame: predose and weekly through Week 4

  4. Pain assessments

    Latency to first feel pain and pain intensity scoring using the McGill Pain Questionnaire

    Time frame: predose and weekly through Week 4

  5. Safety and tolerability assessment

    Daily questions via CAROMA system

    Time frame: Predose and Daily

Secondary outcomes

  1. Daily diary report

    Examination of clinically relevant phenotypes by daily diary reports of alcohol use, alcohol craving, anxiety, depression, subjective pain and sleep

    Time frame: predose and weekly through Week 4

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Jun 2027, 20 months later.

Of 134 phase 2 interventional studies under Alcoholism, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Nov 29, 2024
StartEst.
Oct 1, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06710431
Lead sponsor
Afasci Inc
Responsible party
Sponsor
First posted
Nov 29, 2024
Start date
Oct 1, 2025 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 29, 2024

Study contacts

Simon Xie, MD
Contact
simonxie@afasci.com
650-995-7320
Lara Ray, MD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AFA-281

Start the discussion